Navigation Links
Renewal of agreement between Ipsen and the Salk Institute supports cutting-edge research
Date:7/12/2011

La Jolla----Ipsen and the Salk Institute for Biological Studies announced today that they are renewing the Ipsen Life Sciences Program at the Salk Institute. The mission of the partnership is to advance knowledge in the field of proliferative and degenerative diseases through fundamental and applied biology research.

The Ipsen Life Sciences Program led by the Salk Institute's Inder Verma, Ph.D., Irwin and Joan Jacobs Chair in Exemplary Science will for a period of three years, sponsor four research programs through targeted and innovation grants. Ipsen will provide funding for targeted research programs carried out at the Salk Institute by researchers on novel therapeutic concepts for the treatment of pituitary adenomas, cancer and neurodegenerative diseases. Innovation grants will fund the exploration of advanced scientific concepts. Dr. Verma is one of the world's leading authorities in cancer biology.

Over the last 3 years, the partnership between the Salk Institute and Ipsen has delivered significant scientific advances in the cancer field such as the development of biological models mimicking human cancerous processes as well as identification of specific cells driving tumor growth. In addition, the development of stem cells technology has opened up promising new vistas of research in neurodegenerative diseases.

Marc de Garidel, Chairman and Chief Executive Officer of Ipsen, stated "At a time when the magnitude and scope of the life sciences revolution challenge the imagination, it is critical for a biopharmaceutical company to secure close links with the leading academic institutions worldwide. The collaboration between Ipsen and the Salk Institute perfectly fits in our new strategy of increased focus on our key assets, investment in growth levers and leverage of our footprint. By capitalizing on partnerships with first-class research organizations, Ipsen will strengthen its links with the medical and scientific community so as
'/>"/>

Contact: Andy Hoang
ahoang@salk.edu
619-861-5811
Salk Institute
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Erg gene key to blood stem cell self-renewal
2. UNC awarded $6.2 million renewal grant by NIH Rare Diseases Research Network
3. MU signs $5 million agreement with Coulter Translational Research Partnership Program
4. Epitomics Signs Agreement With Bayer for Antibody Technology
5. PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. Enter into a Licensing and Collaboration Agreement on PEP02 (MM-398), Nanoliposomal Irinotecan
6. NextCAT secures license agreement for advanced biofuel technology from Wayne State
7. DSM and Codexis Sign Enzyme Supply Agreement
8. Ben-Gurion U. and PTT Chemical sign R&D agreement to commercialize green algae strain
9. DSM and Codexis Sign Enzyme Supply Agreement
10. Sangart, Inc. Announces Cooperative Research and Development Agreement With the U.S. Navy to Evaluate MP4 Molecule in Traumatic Brain Injury
11. Agilent Technologies Expands Agreement to Offer AMDeC Members Preferential Pricing on Products Through AMDeC F.I.R.S.T.™ Vendor Partnership Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... A UT Arlington environmental engineer has been awarded ... District to ensure water quality and flow in ... Project. , Andrew Kruzic, UT Arlington associate professor ... and locations to add monochloramine to the water ... the new pump stations and pipelines. Adding monochloramine ...
(Date:6/18/2013)... $12.7 million to match nine academic research groups ... explore new treatments for patients in eight disease ... schizophrenia. The collaborative pilot initiative, called Discovering New ... the National Center for Advancing Translational Sciences (NCATS) ... The process of developing a new therapeutic is ...
(Date:6/18/2013)... and 10% of breast and ovarian cancers are familial ... are attributable to inherited mutations from the parents in ... these mutations, PARP inhibitors, which are currently in clinical ... new option for personalised cancer treatment, an alternative to ... fraction of these patients generate resistance to the drug ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... the sun's heat on weather balloons largely accounts for ... dispute over the existence of global warming, according to ... National Oceanic and Atmospheric Administration (NOAA). , The report, ... direct heat of the sun on temperature probes of ...
... times and until our very own day, been considered ... every growing thing in their path. , Until now, ... were predominantly directed by prevailing winds. Now, Hebrew University ... of these grasshoppers ?namely their polarization vision -- provides ...
... Alberta research team has discovered important new information they ... arterial hypertension (PAH)--a deadly form of high blood pressure ... Therapies are currently limited for a disease that can ... years. , The researchers have shown that Survivin, a ...
Cached Biology News:Errors in the measurement of global warming corrected 2Locusts' built-in 'surface analysis' ability directs them to fly overland 2Researchers develop gene therapy to reverse pulmonary arterial hypertension 2Researchers develop gene therapy to reverse pulmonary arterial hypertension 3
(Date:6/18/2013)... -- RegeneCure announced today the start ... Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid ... encountered when patients have a tooth replaced with a dental ... the implant. Consequently there is often a need to support ... regenerates. The bone substitute material, in turn, needs to be ...
(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...
(Date:6/18/2013)... , June 18, 2013 ... ) has announced the addition of the ... [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & ... & Auto Injectors] & Therapeutics [Diabetes & ... report to their offering.      ...
(Date:6/18/2013)... Inflamax Research Inc., a full ... Phase I-IV clinical trials, announced today that they ... Environmental Technologies (NAET), a specialty air conditioning & ... servicing of mobile Environmental Exposure Chambers (EECs) used ... , Inflamax Research has proprietary Next ...
Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... Mo., Nov. 7 In refusing to a ... removal and replacement of its,current directors, management of ... developer and manufacturer of diagnostic products whose,American Depository ... that the preservation of their jobs and positions ...
... is an observational study undertaken to evaluate the, ... freezing) techniques, ROCKLAND, Mass., Nov. 7 /PRNewswire/-- ... Darmstadt, Germany, announced the launch of the Human,Oocyte ... Meeting of the American Society for Reproductive Medicine ...
... Calif., Nov. 7 AutoImmune Inc. (OTC,Bulletin Board: AIMM) today ... basic and diluted, for the three months ended September 30, ... per share basic and,diluted, for the three months ended September ... net loss was $216,000, or $0.01 per share,basic and diluted, ...
Cached Biology Technology:Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders 2Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders 3EMD Serono Launches Landmark Patient Registry for Egg Freezing 2EMD Serono Launches Landmark Patient Registry for Egg Freezing 3EMD Serono Launches Landmark Patient Registry for Egg Freezing 4AutoImmune Inc. Reports 2008 Third Quarter Financial Results 2AutoImmune Inc. Reports 2008 Third Quarter Financial Results 3
Blue Standard is 3-cyano-7-hydroxycoumarin....
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: